The Use of Gene Therapy for Ablation of Atrial Fibrillation
Department of Medicine, Division of Cardiovascular Medicine
Cardiology | Cardiovascular Diseases | Genetic Phenomena | Genetics and Genomics | Therapeutics
Atrial fibrillation is the most common clinically significant cardiac arrhythmia, increasing the risk of stroke, heart failure and morbidity and mortality. Current therapies, including rate control and rhythm control by antiarrhythmic drugs or ablation therapy, are moderately effective but far from optimal. Gene therapy has the potential to become an attractive alternative to currently available therapies for atrial fibrillation. Various gene transfer vectors have been developed for cardiovascular disease with viral vectors being most widely used due to their high efficiency. Several gene delivery methods have been employed on different therapeutic targets. With increasing understanding of arrhythmia mechanisms, novel therapeutic targets have been discovered. This review will evaluate state-of-art gene therapy strategies and approaches including sinus rhythm restoration and ventricular rate control that could eventually prevent or eliminate atrial fibrillation in patients.
Atrial fibrillation, arrhythmia, gene therapy, heart, vector
DOI of Published Version
Arrhythm Electrophysiol Rev. 2014 Nov;3(3):139-44. doi: 10.15420/aer.2014.3.3.139. Epub 2014 Nov 29. Link to article on publisher's site
Arrhythmia and electrophysiology review
Liu, Zhao and Donahue, J. Kevin, "The Use of Gene Therapy for Ablation of Atrial Fibrillation" (2014). Cardiovascular Medicine Publications and Presentations. 106.